Clostridium difficile TcdB is a key virulence factor that causes C. difficile-associated diseases. Our previous studies have shown that recombinant full-length TcdB (rTcdB) induces cell death in CT26 cells, and rTcdB-treated CT26 cells with high immunogenicity could stimulate dendritic cell (DC) activation and T cell activation in vitro. The rTcdB-treated CT26 cells also induce antitumor immunity in mice and protect mice from CT26 cells. High-mobility group box 1 protein (HMGB1) is a non-histone nuclear protein, which has various biological functions within the nucleus and also acts as an extracellular signal molecule involving in inflammatory diseases, cancers or autoimmune diseases. In this study, HMGB1 was found to be released from the rTcdB-treated CT26 cells. HMGB1 knockdown by using specific siRNA weakened the capacity of the BMDCs loaded with the rTcdB-treated CT26 cells to prime T cells in vitro and in vivo. The released HMGB1 from CT26 cells could interact with the receptor TLR4, which is closely related to DC activation and immune responses. The knockdown of HMGB1 also affected the phagocytosis of the rTcdBtreated CT26 cells by DCs in vitro. Furthermore, HMGB1 weakened the antitumor immunity of the rTcdB-treated CT26 cells, which protects mice from rechallenge of the live CT26 cells. Taken together, these results suggest that HMGB1 plays an important role on the immunogenicity of the rTcdB-treated dying CT26 cells.
Introduction
Clostridium difficile is the most common cause of nosocomial antibiotic-associated diarrhea and pseudomembranous colitis [1] [2] [3] . Toxin B (TcdB) with high cytotoxicity is thought to be one of the key virulent factors of C. difficile infection. TcdB could induce intestinal epithelial cell damage and the release of inflammatory cytokines, thus trigging inflammatory and immune response [4] [5] [6] [7] [8] . Our previous studies have shown that rTcdB-treated CT26 cells can stimulate dendritic cell (DC) and T cell activation in vitro, induce antitumor immunity in vivo and protect mice from a lethal challenge of CT26 cells [9, 10] . These findings suggested that rTcdB could induce immunogenic cell death (ICD) in CT26 cells, which may have profound implications for the design of new cancer therapeutics. However, the mechanism through which rTcdB-treated CT26 cells induce antitumor immunity is still unclear.
According to the accepted models, ICD induced by chemotherapeutic agents relies on the early surface exposure of chaperones including calreticulin (CRT) and HSPs (HSP70 and HSP90), and the late release of high-mobility group box 1 (HMGB1) [11] [12] [13] . HMGB1 is a ubiquitous and abundant nuclear protein, which has various biological functions within the nucleus, such as binding to DNA without sequence specificity, regulating transcription, replication and DNA repair [14] [15] [16] . In dying tumor cells, HMGB1 was found to be released into the local microenvironment and acts as an extracellular danger signal molecule that binds to several pattern recognition receptors, such as Toll-like receptors (TLR2 and TLR4), and the receptor for advanced glycosylation end products (RAGE) [17] [18] [19] . Hence, the release of HMGB1 is thought to be required for optimal presentation of antigen from dying tumor cells, T cell priming by DCs, and subsequent T cell mediated elimination of the tumor.
In this study, HMGB1 was found to be remarkably released from rTcdB-treated CT26 cells. The role of HMGB1 in DC activation and the presentation of antigen in vitro as well as the in vivo antitumor activity in rTcdB-treated CT26 cells were examined. These together provide more evidence on the functional implications of HMGB1 in ICD induced by rTcdB.
Materials and Methods

Animals, cell lines and recombinant toxins
Six to eight-week-old BALB/c mice (SPF) were obtained from Guangdong Medical Laboratory Animal Center (Guangzhou, China). All mice used in this study were cared for according to the China Animal Care and Use Committee Guidelines. Food, water, bedding and cages were autoclaved.
The mouse colon carcinoma cell line (CT26) and the murine macrophage cell line (RAW264.7) were purchased from the American Type Culture Collection (Manassas, USA) and cultured in Dulbecco's modified Eagle's medium (GIBCO, New York, USA) supplemented with 10% fetal bovine serum (FBS; GIBCO), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate (GIBCO) in 100-mm culture plates at 37°C and 5% CO 2 .
DCs generated from BALB/c mouse bone marrow were prepared as previously described [20] . Bone marrow-derived DCs (BMDCs) were cultured in RPMI 1640 medium (GIBCO) supplemented with 10% FBS, 1% penicillin-streptomycin, GM-CSF (10 ng/ml) and IL-4 (10 ng/ml), which were replenished on Days 2 and 4 of a 6-day culture.
The recombinant full-length TcdB (rTcdB) was obtained and purified from total crude extract of Bacillus megaterium as described previously [21] . The purity of rTcdB was assessed by gel electrophoresis with a single band.
Cytopathic and cytotoxic assays
The cytopathic and cytotoxic effects of rTcdB on CT26 cells were assessed as described previously [22] . Subconfluent CT26 cells seeded in 96-well plate were incubated with rTcdB for different exposure times. The cytopathic effect of the rTcdB was examined by cell-rounding assay by phase-contrast microscopy (Olympus, Tokyo, Japan). The cytotoxic effect was assessed by MTT assay. Formazan was solubilized with dimethyl sulphoxide and absorbance at 490 nm was measured using a SpectraMax M5 microplate reader (Molecular Devices, San Francisco, USA). The results are presented as the percentage of survival cells compared to untreated cells. The experiments were repeated three times, and triplicate wells were assessed for the MTT assay and cell-rounding assay in each experiment.
Western blot analysis
The CT26 cells treated with 100 ng/ml rTcdB for different times were washed with phosphate-buffered saline (PBS) and lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% Nonidet P-40, 1 mM ethylenediaminetetraacetic acid and 0.1% SDS). The total proteins were separated by 12% SDS-PAGE and transferred to nitrocellulose filter membranes. The membranes were blocked with 5% nonfat dry milk in PBS and incubated with primary antibodies anti-HMGB1 (Cell Signaling Technology, Beverly, USA), β-actin or BSA (Abcam, Cambridge, USA) and then with the HRP-conjugated secondary antibodies (Cell Signaling Technology). β-Actin and BSA were used as internal loading controls. Immunological bands were visualized with a SuperSignal West Pico Chemiluminescent Substrate Kit (Thermo Scientific, Waltham, USA) following the manufacturer's instructions. Fold-change values were normalized by β-actin or BSA using ImageJ software.
siRNA transfection and rTcdB treatment
To achieve the knockdown of HMGB1, CT26 cells were seeded at a density of 1 × 10 5 cells/well in 24-well plate to achieve more than 30%-50% confluence before transfection. For transfection, the Lipofectamine 2000 (Invitrogen, Carlsbad, USA) was mixed with PBS, HMGB1 siRNA (5′-GCUGAAAAGAGCAAGAAAATT-3′, siRNA) or irrelevant siRNA (5′-CUUACGCUGAGUACUUCGATT-3′, coRNA) gently at room temperature in the Opti-MEMI serum-free medium (Invitrogen, Carlsbad, USA) for 20 min. The cells were then transfected with different mixtures and incubated at 37°C in an atmosphere of 5% CO 2 for 6 h, after which the medium was changed to complete medium.
For the preparation of rTcdB-treated CT26 cells, the CT26 cells transfected with PBS, siRNA or coRNA were incubated with 100 ng/ml rTcdB at 37°C for 6 h, and then collected for further investigation.
Stimulation of autologous T cells by tumor-loaded DCs in vitro
DCs were incubated with live or rTcdB-treated CT26 cells overnight in 24-well plate at a ratio of 1:1. Spleens harvested from 6-to 8-week-old healthy BALB/c mice were ground, filtered and treated with erythrocyte lysate under asepsis condition, to obtain the single-cell suspension of splenocytes. Tumor-loaded DCs were co-cultured with splenocytes at a ratio of 1:10 in 24-well plate. Mouse recombinant IL-2 (50 IU/ml; Invitrogen) was added into the culture on the second day and fifth day and the splenocytes were restimulated using the same antigen presenting cells as the initial stimulation on the seventh day. After another seven days of culture, the supernatants were collected for measuring of IFN-γ production by ELISA.
Antigen presentation assay in vivo
Experimental and control groups of BALB/c mice were injected subcutaneously with rTcdB-treated CT26 cells (10 6 cells/mouse) or PBS, respectively. Splenocytes were harvested from immunized mice 5 days after the second immunization and co-cultured with CT26 cells at a ratio of 10:1 or the irrelevant antigen ovalbumin (OVA). IFN-γ concentrations in the supernatant were analyzed 3 days later by ELISA. The antibodies used in this assay included the anti-IFN-γ capture antibody (BD Biosciences, Franklin Lakes, USA) and biotinylated anti-IFN-γ antibody (BD Biosciences).
Immunoprecipitation assay
Immunoprecipitation assay was carried out as described previously [23] . RAW264.7 cells incubated with the supernatants of either live CT26 cells or rTcdB-treated CT26 cells for 30 or 60 min before harvest were lysed in lysis buffer containing a protease inhibitor cocktail. The whole-cell extracts were centrifuged at 14,000 g for 20 min and the debris was removed. The samples were incubated with anti-TLR4 antibody at 4°C overnight and then mixed with 15 μl protein A/G plus-agarose beads. The pellets were collected from the mixtures by centrifugation, washed and resuspended in 20 μl of 2 × SDS loading buffer. The protein samples were then detected by western blot analysis using an anti-TLR4 antibody (dilution 1:1000) and anti-HMGB1 antibody (dilution 1:1000).
Phagocytosis assay
CT26 cells were stained with carboxyfluorescein diacetate succinimidyl esters (CFSE; Invitrogen) as previously described [24] before treated with rTcdB for 6 h. The free rTcdB in the medium was then removed and the CFSE-stained CT26 cells were co-cultured with DCs for 36 h. The mixed cells were harvested and stained with R-phycoerythrin (PE)-conjugated anti-CD11c antibody before analyzed by flow cytometry using fluorescence activated cell sorter (FACSCalibur) and CellQuest software (BD Biosciences).
In vitro DC maturation assay
To measure the DC maturation induced by rTcdB-treated CT26 cells, immature DCs obtained as described above were co-cultured with rTcdB-treated CT26 cells for 36 h at a 1:1 ratio. The mixed cells were harvested, blocked with 5% BSA and then dually stained with PE-conjugated anti-CD11c mAb and fluorescein isothiocyanate (FITC)-conjugated anti-CD40 mAb or anti-CD86 mAb for 30 min at 4°C. The cells were washed twice with phosphate buffer containing 1% BSA and analyzed by flow cytometry using FACSCalibur and CellQuest software.
Mouse immunization and challenge
PBS or rTcdB-treated CT26 cells (10 6 cells/ mouse) were injected subcutaneously into the right groins of BALB/c mice twice (first and eighth day). Seven days after the second immunization (referred to as Day 0 of challenge), mice were inoculated with a total of 10 5 (LD 100 ) live CT26 cells in the right flank. The tumor size was measured every two days using a caliper and the tumor volume was calculated as previously described [25] . Animals bearing tumors in excess of 20%-25% of the body mass or at the end of the observation period were sacrificed.
Statistical analysis
Results are expressed as the mean ± standard error unless otherwise indicated. Statistical analysis was performed using Kaplan-Meier survival analysis, Student's t-test or one-way ANOVA assay. All statistical analyses were performed the GraphPad Prism software. A P-value < 0.05 was considered statistically significant for all experiments.
Results
The release of HMGB1 in rTcdB-treated CT26 cells
Recombinant full-length TcdB was expressed in a B. megaterium expression system as previously described [21] and purified using affinity chromatography. The purified rTcdB and its cytopathic and cytotoxic assays on CT26 cells as shown in Supplementary Fig. S1 indicate the high sensitivity of CT26 cells to the recombinant TcdB proteins.
The expression and release of HMGB1 in rTcdB-treated CT26 cells were analyzed at different time points. After rTcdB treatment, the intracellular expression levels of HMGB1 were detected by western blot analysis and the cell membrane skeleton protein β-actin was used as a loading control. It was found that longer time of rTcdB treatment results in the increase in intracellular HMGB1 level in CT26 cells in the first 8 h and then the expression level was decreased (Fig. 1A,C) . The HMGB1 level in the culture supernatants was detected at 12 h and showed an increasing trend with increasing treatment time (Fig. 1B,D) . These results show that treatment with rTcdB promotes the release of HMGB1 from CT26 cells in a time-dependent manner. The reduced expression of HMGB1 in the cells after 8 h might be attributable to the increased release of HMGB1 into the culture medium.
The effect of HMGB1 knockdown on the immunostimulation of rTcdB-treated CT26 cells in vitro
To investigate the role of HMGB1 for rTcdB-treated CT26 cells, a HMGB1-specific siRNA was used to delete HMGB1 expression in CT26 cells (Fig. 1E,F) . Compared to the control group (transfected with PBS) or the coRNA group (transfected with an irrelevant siRNA), the intracellular and extracellular HMGB1 expression levels in the siRNA group (transfected with HMGB1-specific siRNA) were almost at an undetectable level, indicating the successful construction of the knockdown system.
Our previous study revealed that BMDCs loaded with rTcdBtreated CT26 cells could significantly enhance IFN-γ production by T cells, indicating that the rTcdB-treated CT26 cells could stimulate the activation of BMDCs and subsequent T cell activation [10] . To determine the effect of HMGB1 knockdown on the immunostimulation caused by rTcdB-treated CT26 cells, we examined the ability of the BMDCs loaded with rTcdB-treated siRNA-transfected CT26 cells to prime T cells for IFN-γ production. As shown in Fig. 2 , the rTcdB-treated CT26 cells did not produce a detectable amount of IFN-γ in the absence of BMDCs. BMDCs loaded with rTcdB-treated CT26 cells, but not with live CT26 cells, could significantly enhance IFN-γ production, suggesting that rTcdB-treated CT26 cells could induce IFN-γ production by T cells via activation of BMDCs. In addition, BMDCs loaded with rTcdB-treated siRNA-transfected CT26 cells significantly inhibited the production of IFN-γ. These results revealed that the siRNA-mediated knockdown of HMGB1 weakened the capacity of BMDCs loaded with the rTcdB-treated CT26 cells to prime T cells for IFN-γ production in vitro, which suggested that HMGB1 might participate in the stimulation of T cells by tumor-loaded DCs.
Enhancement of T cell responses in vivo by HMGB1 expression and release
To determine whether HMGB1 could affect T cell responses in vivo, we immunized mice with rTcdB-treated CT26 cells (the control group), rTcdB-treated siRNA-transfected CT26 cells (the siRNA group), rTcdB-treated coRNA-transfected CT26 cells (the coRNA group) and PBS (the PBS group). The harvested splenocytes were then restimulated in vitro with PBS, CT26 cells or OVA, respectively. Compared to splenocytes from mice in the PBS group, the control group showed significantly higher IFN-γ production when restimulated with CT26 cells, suggesting that rTcdB-treated CT26 cells could specifically stimulate the T cell responses in vivo (Fig. 3) . However, splenocytes from mice in the siRNA group Figure 2 . Effect of HMGB1 knockdown on T cell activation in vitro Autologous splenocytes were co-cultured with BMDCs loaded with differently treated CT26 cells for 2 weeks, and the supernatant was collected to measure IFN-γ production by ELISA. Data are presented as the mean ± standard error of three biological replicates. *P < 0.05; ns, no significant difference. On Day 5, the splenocytes were harvested and restimulated in vitro. The experiment in vivo involved three mice per group and data are presented as the mean ± standard error of triplicates. ***P < 0.001; ns, no significant difference.
showed significantly lower IFN-γ production as compared to the control group but showed significantly higher IFN-γ production than those from the mice immunized with PBS. Taken together, these results showed that rTcdB-treated CT26 cells could specifically stimulate the T cell responses in vivo and HMGB1 release from rTcdB-treated CT26 cells plays an important role on the T cell activation in vivo.
Interaction between HMGB1 and TLR4
To investigate the mechanism of HMGB1 in the activation of T cells, we checked the interaction of HMGB1 released by rTcdB-treated CT26 cells with Toll-like receptor 4 (TLR4) which is selectively involved in the cross-priming of antitumor T lymphocytes in vivo.
The supernatants of rTcdB-treated CT26 cells were collected and coincubated with RAW264.7 cells for 30 or 60 min. As shown in Fig. 4 , HMGB1 released from rTcdB-treated CT26 cells could directly interact with the TLR4 presented on RAW264.7 cells, as identified by immunoprecipitation assay using anti-TLR4 or anti-HMGB1 antibody. These data suggested that HMGB1 released from rTcdBtreated CT26 cells is probably responsible for TLR4-dependent antigen presentation processing, thus eliciting immune responses.
HMGB1 suppresses the phagocytosis of rTcdB-treated CT26 cells by DCs
Previous studies have shown that rTcdB-treated CT26 cells undergo immunogenic apoptosis, thereby stimulating the immune system Data are presented as the mean ± standard error from three independent experiments. *P < 0.05; ***P < 0.001; ns, no significant difference. (C) For DC maturation analysis, the mixed cells were dually stained with PE-conjugated anti-CD11c and FITC-conjugated anti-CD40 or anti-CD86, and the surface expression of CD40 or CD86 on DCs were analyzed by FACS. (D) The fluorescence intensities of CD40 or CD86. Data are presented as the mean ± standard error from two independent experiments. *P < 0.05; **P < 0.01; ns, no significant difference. [9, 10] . DCs play critical roles in initiating immune response, and stressed apoptotic tumor cells are capable of activating DCs [26, 27] . Next, we determined whether the HMGB1 released from the rTcdBtreated CT26 cells impacts phagocytosis in vitro. As shown in Fig. 5A ,B, CFSE-labeled rTcdB-treated CT26 cells were phagocytized by CD11c-positive DCs. The percentage of phagocytosis in the siRNA group was 31.33% which was slightly higher than that of the control (27.51%) or the coRNA group (26.49%), suggesting that the release of HMGB1 might protect the rTcdB-treated CT26 cells from phagocytosis by DCs.
HMGB1 does not affect DC maturation induced by rTcdB-treated CT26 cells
The rTcdB-treated CT26 cells have the potent capacity to induce DC maturation [9, 10] . To determine whether the HMGB1 released from the rTcdB-treated CT26 cells plays a role on DC maturation, the expression of surface co-stimulatory molecules CD86 and CD40 were measured by flow cytometry. As shown in Fig. 5C ,D, the rTcdB-treated CT26 cells in the control group induced an increased expression of CD86 or CD40. However, no significant difference was found among the control, the siRNA and the coRNA groups, suggesting that the depletion of HMGB1 had no significant effect on DC maturation induced by rTcdB-treated CT26 cells.
HMGB1 knockdown affects the antitumor immunity of rTcdB-treated CT26 cells in vivo
The rTcdB-treated CT26 cells could act as a tumor vaccine and protect against a subsequent challenge with live CT26 cells [10] . A vaccine model was used to assess the role of HMGB1 in the antitumor immunity induced by rTcdB-treated CT26 cells. The percentages of tumor-free mice and tumor sizes were monitored. As shown in Fig. 6A , the percentage of tumor-free mice in the siRNA group was 37.5%, whereas the percentage of tumor-free mice in coRNA group was 75% and no mice developed tumors among the control groups vaccinated with rTcdB-treated CT26 cells. The tumor volumes of mice also showed the similar results (Fig. 6B) . These results indicated that the antitumor effect of rTcdB intoxicated cells was partially lost when the expression of HMGB1 was silenced in the intoxicated CT26 cells.
Discussion
ICD with potential in antitumor immunity and cancer therapy has been studied in the last few years [28] . The inoculation of cancer cells undergoing ICD into immunocompetent animals elicits a specific immune response associated with the establishment of immunological memory [29] [30] [31] [32] . Based on our previous studies, rTcdB can induce cell death in CT26 cells, and rTcdB-treated CT26 cells are highly immunogenic and stimulate potent antitumor immunity in vitro and in vivo [9, 10] . Whether the mechanism of the antitumor immunity induced by intoxicated tumor cells is similar to that by chemotherapeutic agents [33] [34] [35] or some specific forms of irradiation and photodynamic therapy [36, 37] is still unclear. HMGB1 senses the cellular stress response and plays a critical role not only as a DNA chaperone, chromosome guardian, autophagy sustainer and protector from apoptotic cell death, but also as a prototypic damage-associated molecular pattern molecule [38] . HMGB1 is released not only from the immune cells such as activated macrophages, DCs and NK cells, but also from the necrosis or apoptotic cells [39] [40] [41] [42] [43] [44] . It has been suggested that HMGB1 molecules might determine the immunogenicity of dying tumor cells [45] . Our previous study revealed that HMGB1 could also affect early inflammatory factors and induce inflammation in the acute inflammatory responses to recombinant C. difficile toxin A (rTcdA) [46] . In the present study, we evaluated the contribution of released HMGB1 to the immunity of rTcdB-treated CT26 cells. Under rTcdB treatment, HMGB1 was found to be released into culture supernatants. In a previous report, irradiation of EG7 cells or doxorubicin treatment of CT26 cell was found to promote the release of HMGB1 [18] . We also found that the released HMGB1 existed in rTcdB-treated HT29 cells, HCT8 cells and B16F10 cells (data not shown). In combination with previously reports [39, 40] , these results indicated that the release of HMGB1 might not depend on specific types of the stimuli or target tumor cells but commonly existed in dying tumor cells.
The release of HMGB1 by dying tumor cells exposed to some chemotherapeutic agents is vital to promote antigen processing by DCs and hence contributes to efficient antigen presentation and cytotoxic T cell activation, which is mediated by TLR4 on DCs [18] . HMGB1 released by rTcdB-treated CT26 cells also participates in inducing T cell activation in vitro. To evaluate the in vivo influence of the HMGB1 release, we immunized mice with rTcdB-treated CT26 cells after siRNA knockdown of HMGB1 in these cells. The results revealed that the priming of T cells by BMDCs loaded with the rTcdB-treated dying CT26 cells required the release of HMGB1 and that HMGB1 knockdown could weaken the capacity of rTcdBtreated CT26 cells to protect mice against rechallenge with CT26 cells. We also provided the evidence of physical interaction between HMGB1 released by rTcdB-treated CT26 cells and TLR4. These results taken together with previous studies suggest that the immune effect of rTcdB-treated CT26 relies on the release of HMGB1 (the 'danger' signal), which is probably responsible for TLR4-dependent antigen presentation processing [9] . DC activation plays critical roles in initiating the immune response. Dying rTcdB-treated CT26 cells are capable of stimulating DC phagocytosis and DC maturation [9] . In the present study, we found that rTcdB-treated CT26 cells with knockdown of HMGB1 could slightly enhance phagocytosis capacity. The HMGB1 C-terminal tail, which can bind to the RAGE receptor involved in efferocytosis, was thought to be responsible for the inhibitory effects of HMGB1 on phagocytosis of apoptotic neutrophils [47] . HMGB1 released by rTcdB-treated CT26 cells did not affect the inducing capacity for the maturation of DCs, which was consistent with a previous study [18] . These results suggest that HMGB1 may have slight effects on the activation of DCs by rTcdB-treated CT26 cells.
Altogether, these data illustrate the release of HMGB1 from rTcdB-treated CT26 cells, which is vital to the immunogenicity of the rTcdB-treated CT26 cells, especially in antigen presentation and cytotoxic T cell activation. Because of its important roles in antitumor immune response, HMGB1 could act as an immune-adjuvant for immunotherapy of cancer, which might enhance adaptive effector and immune responses. This study therefore highlights the contribution of HMGB1 in immunogenicity of rTcdB-treated CT26 cells and may be helpful in uncovering the mechanism of ICD and provides novel insights into autoimmunity and vaccine improvement.
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